Acyclovir achieves a lower concentration in African HIV-seronegative, herpes simplex virus 2-seropositive women than in non-African populations

Yanhui Lu; Connie Celum; Anna Wald; Jared M. Baeten; Frances Cowan; Sinead Delany-Moretlwe; Stewart E. Reid; James P. Hughes; Ellen Wilcox; Lawrence Corey; Craig W. Hendrix

doi:10.1128/aac.06160-11

Acyclovir achieves a lower concentration in African HIV-seronegative, herpes simplex virus 2-seropositive women than in non-African populations

Yanhui Lu
, Connie Celum
, Anna Wald
, Jared M. Baeten
, Frances Cowan
, Sinead Delany-Moretlwe
, Stewart E. Reid
, James P. Hughes
, Ellen Wilcox
, Lawrence Corey
, Craig W. Hendrix

Johns Hopkins University
University of Washington
University College London
University of Zimbabwe
University of the Witwatersrand
University of Alabama at Birmingham
Centre for Infectious Disease Research in Zambia

Research output: Contribution to journal › Article › peer-review

25 Citations (Scopus)

Abstract

Acyclovir pharmacokinetics was evaluated in 68 HIV-seronegative, herpes simplex virus 2 (HSV-2)-seropositive African women, who received a single oral 400-mg dose of acyclovir, with plasma acyclovir concentrations measured over 8 h. Geometric mean peak concentration and area under the concentration-time curve were 0.31 μg/ml and 1.59 h · μg/ml, respectively, 54% and 52% lower than values from non-Africans. Lower acyclovir concentrations may partly explain the reduced acyclovir suppression of HSV-2 genital ulcer recurrence in HPTN 039 African women participants.

Original language	English
Pages (from-to)	2777-2779
Number of pages	3
Journal	Antimicrobial Agents and Chemotherapy
Volume	56
Issue number	5
DOIs	https://doi.org/10.1128/aac.06160-11
Publication status	Published - 1 May 2012
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1128/aac.06160-11

Cite this

Lu, Y., Celum, C., Wald, A., Baeten, J. M., Cowan, F., Delany-Moretlwe, S., Reid, S. E., Hughes, J. P., Wilcox, E., Corey, L., & Hendrix, C. W. (2012). Acyclovir achieves a lower concentration in African HIV-seronegative, herpes simplex virus 2-seropositive women than in non-African populations. Antimicrobial Agents and Chemotherapy, 56(5), 2777-2779. https://doi.org/10.1128/aac.06160-11

@article{83367f7db92d4baa89f0b338900442ee,

title = "Acyclovir achieves a lower concentration in African HIV-seronegative, herpes simplex virus 2-seropositive women than in non-African populations",

abstract = "Acyclovir pharmacokinetics was evaluated in 68 HIV-seronegative, herpes simplex virus 2 (HSV-2)-seropositive African women, who received a single oral 400-mg dose of acyclovir, with plasma acyclovir concentrations measured over 8 h. Geometric mean peak concentration and area under the concentration-time curve were 0.31 μg/ml and 1.59 h · μg/ml, respectively, 54\% and 52\% lower than values from non-Africans. Lower acyclovir concentrations may partly explain the reduced acyclovir suppression of HSV-2 genital ulcer recurrence in HPTN 039 African women participants.",

author = "Yanhui Lu and Connie Celum and Anna Wald and Baeten, \{Jared M.\} and Frances Cowan and Sinead Delany-Moretlwe and Reid, \{Stewart E.\} and Hughes, \{James P.\} and Ellen Wilcox and Lawrence Corey and Hendrix, \{Craig W.\}",

year = "2012",

month = may,

day = "1",

doi = "10.1128/aac.06160-11",

language = "English",

volume = "56",

pages = "2777--2779",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "5",

}

Lu, Y, Celum, C, Wald, A, Baeten, JM, Cowan, F, Delany-Moretlwe, S, Reid, SE, Hughes, JP, Wilcox, E, Corey, L & Hendrix, CW 2012, 'Acyclovir achieves a lower concentration in African HIV-seronegative, herpes simplex virus 2-seropositive women than in non-African populations', Antimicrobial Agents and Chemotherapy, vol. 56, no. 5, pp. 2777-2779. https://doi.org/10.1128/aac.06160-11

TY - JOUR

T1 - Acyclovir achieves a lower concentration in African HIV-seronegative, herpes simplex virus 2-seropositive women than in non-African populations

AU - Lu, Yanhui

AU - Celum, Connie

AU - Wald, Anna

AU - Baeten, Jared M.

AU - Cowan, Frances

AU - Delany-Moretlwe, Sinead

AU - Reid, Stewart E.

AU - Hughes, James P.

AU - Wilcox, Ellen

AU - Corey, Lawrence

AU - Hendrix, Craig W.

PY - 2012/5/1

Y1 - 2012/5/1

N2 - Acyclovir pharmacokinetics was evaluated in 68 HIV-seronegative, herpes simplex virus 2 (HSV-2)-seropositive African women, who received a single oral 400-mg dose of acyclovir, with plasma acyclovir concentrations measured over 8 h. Geometric mean peak concentration and area under the concentration-time curve were 0.31 μg/ml and 1.59 h · μg/ml, respectively, 54% and 52% lower than values from non-Africans. Lower acyclovir concentrations may partly explain the reduced acyclovir suppression of HSV-2 genital ulcer recurrence in HPTN 039 African women participants.

AB - Acyclovir pharmacokinetics was evaluated in 68 HIV-seronegative, herpes simplex virus 2 (HSV-2)-seropositive African women, who received a single oral 400-mg dose of acyclovir, with plasma acyclovir concentrations measured over 8 h. Geometric mean peak concentration and area under the concentration-time curve were 0.31 μg/ml and 1.59 h · μg/ml, respectively, 54% and 52% lower than values from non-Africans. Lower acyclovir concentrations may partly explain the reduced acyclovir suppression of HSV-2 genital ulcer recurrence in HPTN 039 African women participants.

U2 - 10.1128/aac.06160-11

DO - 10.1128/aac.06160-11

M3 - Article

SN - 0066-4804

VL - 56

SP - 2777

EP - 2779

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

IS - 5

ER -

Acyclovir achieves a lower concentration in African HIV-seronegative, herpes simplex virus 2-seropositive women than in non-African populations

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this